Compare CDRO & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDRO | CERS |
|---|---|---|
| Founded | 2014 | 1991 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | EDP Services |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.5M | 276.0M |
| IPO Year | N/A | 1997 |
| Metric | CDRO | CERS |
|---|---|---|
| Price | $7.62 | $2.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $9.00 | $4.00 |
| AVG Volume (30 Days) | 52.5K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $207,789,626.00 | $199,191,000.00 |
| Revenue This Year | $10.04 | $25.31 |
| Revenue Next Year | $9.24 | $9.50 |
| P/E Ratio | $92.97 | ★ N/A |
| Revenue Growth | ★ 24.16 | 13.03 |
| 52 Week Low | $5.18 | $1.12 |
| 52 Week High | $8.75 | $2.24 |
| Indicator | CDRO | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 70.91 | 69.58 |
| Support Level | $6.78 | $1.83 |
| Resistance Level | $7.39 | $2.14 |
| Average True Range (ATR) | 0.36 | 0.14 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 81.05 | 88.64 |
Codere Online Luxembourg SA is an international online casino gaming and online sports betting group focused on providing its customers with a safe and enjoyable online gaming experience. It currently operates in Spain, Mexico, Colombia, and Other countries. where it offers its users the ability to play online casino games and bet on sports events. Online casino offerings include the full portfolio of games typically available in land-based casinos, gaming halls and gambling establishments, such as slot machines, table games, and bingo. Online sports betting involves a user placing a wager on an event at some fixed odds determined by Codere Online. The company derives maximum revenue from Mexico.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.